Bloomberg reports contamination at Chinese facilities supplying ingredients used to make compounded GLP-1 drugs, raising questions about the supply chain.
Recap by typeshit. Full story at Bloomberg.com.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Medscape reports that people with hidradenitis suppurativa begin GLP-1 drugs sooner in their disease course than people with psoriasis do.
The October Pharmacy Times Community issue covers clinical topics for pharmacists, from GLP-1 safety questions to everyday medication management.
Loading…